Discovery of a potent olaparib–chlorambucil hybrid inhibitor of PARP1 for the treatment of cancer

Introduction: Development of Poly (ADP-ribose) polymerase (PARP) inhibitors has been extensively studied in cancer treatment. Olaparib, the first approved PARP inhibitor, showed potency in the inhibition of both BRCA (breast cancer associated)-mutated and BRCA-unmutated cancers. Methods: Aiming to t...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Hongyu, Zhang, Jian, Zhao, Yilu, Zhang, Lihui, Feng, Jinhong, Zhang, Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9868654/
https://www.ncbi.nlm.nih.gov/pubmed/36699082
http://dx.doi.org/10.3389/fphar.2022.1054616

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9868654/
https://www.ncbi.nlm.nih.gov/pubmed/36699082
http://dx.doi.org/10.3389/fphar.2022.1054616

Ejemplares similares